Your browser doesn't support javascript.
loading
Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
Mukherjee, Debayan; Romano, Erminia; Walshaw, Richard; Zeef, Leo A H; Banyard, Antonia; Kitcatt, Stephen J; Cheadle, Eleanor J; Tuomela, Karoliina; Pendharkar, Swati; Al-Deka, Aws; Salerno, Beatrice; Raby, Sophie; Mills, Ian G; Honeychurch, Jamie; Illidge, Tim M.
Afiliación
  • Mukherjee D; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
  • Romano E; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
  • Walshaw R; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
  • Zeef LAH; Bioinformatics Core Facility, Michael Smith Building, The University of Manchester, Manchester, UK.
  • Banyard A; Mass and Flow Cytometry Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
  • Kitcatt SJ; Scientific Computing Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
  • Cheadle EJ; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
  • Tuomela K; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
  • Pendharkar S; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
  • Al-Deka A; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
  • Salerno B; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
  • Raby S; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
  • Mills IG; Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.
  • Honeychurch J; Patrick G. Johnston Centre for Cancer Research, Queen's University of Belfast, Belfast, UK.
  • Illidge TM; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
Oncoimmunology ; 12(1): 2223094, 2023.
Article en En | MEDLINE | ID: mdl-37332616
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Microambiente Tumoral Tipo de estudio: Clinical_trials Límite: Humans / Male Idioma: En Revista: Oncoimmunology Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Microambiente Tumoral Tipo de estudio: Clinical_trials Límite: Humans / Male Idioma: En Revista: Oncoimmunology Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos